secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001104659-26-014303
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q4 2025 revenue $16.0M (+4% YoY); net loss $11.9M; FY2026 rev guidance $63-67M
--------------------------------------------------------------------------------

- Q4 revenue $16.0M (US $14.9M, Europe $1.1M); gross margin 86% vs 83% YoY.
- Net loss $11.9M ($0.46/sh) vs $10.7M ($0.43/sh) in Q4 2024; full year net loss $53.3M ($2.04/sh).
- Active US implanting centers 252 (up 29 YoY); 53 US sales territories; BENEFIT-HF trial enrollment expected Q2 2026.
- Jan 2026 amended debt facility: added $10M borrowing to $60M total, interest-only period extended, maturity May 2031.
- FY2026 guidance: revenue $63-67M, gross margin 84-86%, op. expenses $103-107M; Q1 2026 revenue expected $13.7-14.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465926014303/0001104659-26-014303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465926014303/tm266143d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-014303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer